Randox Testing Services – Drug and Alcohol Testing
Randox Testing Services – Drug and Alcohol Testing
At Randox Testing Services, we provide reliable and cost-effective drug and alcohol testing solutions for a wide range of industries. Sectors we work with include aviation, maritime, manufacturing, and more. Additionally, our Collection Officer Network operates 24 hours a day, 365 days of the year with a target call-out time of 2 hours. With over 40 years of experience in the diagnostics industry, our services not only ensure safety but also compliance in workplaces across the UK and Ireland.
We understand that every industry has unique needs, which is why we craft customised testing packages to meet specific workplace requirements. Whether it’s random testing to deter substance abuse or post-incident testing following an accident, we offer flexible solutions that cater to your business’s safety priorities. Furthermore, our expertise is trusted by industries ranging from safety-critical sectors to the medico-legal field such as family law, ensuring that our clients receive accurate, reliable, and legally defensible results.
- Pre-Employment Testing: Essential for ensuring candidate suitability and maintaining a safe environment for your current workforce.
- Random Testing: A highly effective deterrent for substance abuse, as employees are aware they could be tested at any time, ensuring integrity across all levels of the organisation.
- With-Cause Testing: Conducted when there is suspicion or allegations of drug or alcohol abuse in the workplace, or when drugs and alcohol have been found.
- Post-Incident Testing: Occurs after an accident or incident to determine if drugs or alcohol played a role.
- Abstinence Testing: Used to monitor employees who previously tested positive to ensure they remain abstinent from substance misuse.
We utilise discreet and non-invasive methods for sample collection, offering options such as urine, hair, oral fluid, breath or a combination of these. This enables both short-term and long-term drug profiling. Moreover, our testing methods are designed to suit your organisation’s needs and ensure accuracy and reliability in detecting drug and alcohol use. Each sample is handled following strict chain of custody procedures to guarantee sample integrity from collection to reporting.
We follow a thorough and professional process to deliver tailored drug and alcohol testing solutions:
-
- Consultation: We start with a free consultation to discuss your requirements and create a customised testing package.
- Policy Creation: We help develop a clear and concise workplace drug and alcohol policy that outlines employer rights while protecting employees.
- Policy Implementation: Our training and educational services help you effectively communicate the policy to your team.
- Sample Collection: Our trained officers collect samples at a time and location that suits you, maintaining sample integrity throughout the process.
- Sample Analysis: Using our advanced Biochip Array Technology, we screen samples for a wide range of substances, ensuring reliable and accurate results.
- Results Reporting: Results are delivered confidentially via our secure web portal, with options for alternative methods if preferred.
We test for a wide range of drugs across different panels using both instant testing kits and lab-based confirmatory analysis. This flexibility allows us to meet the diverse needs of our clients, ensuring all substances of concern are covered. Substances include:
| Substances Tested | |||
|---|---|---|---|
| Amphetamine | Phencyclidine | Alcohol | LSD |
| Buprenorphine | Cannabinoids | Barbiturates | Opioids |
| Benzodiazepine | Oxycodone | Benzodiazepine 1 | Mephedrone |
| Cocaine Metabolite | Tramadol | Benzodiazepine 2 | Pregabalin |
| Methadone | EDDP | Methaqualone | Gabapentin |
| Methamphetamine | Ketamine | Fentanyl | Zolpidem |
| Opiates | MDMA/Ecstasy | Propoxyphene | Zopiclone |
- Expertise across various industries, including workplace and medico-legal
- Accurate and reliable testing methods
- Global network of trained sample collection officers
- Customised training and education seminars
- Free policy review and consultation
Randox Testing Services is committed to helping businesses enhance workplace safety, reduce absenteeism, and ensure compliance with drug and alcohol regulations. Contact us today at testingservices@randox.com or call +44 (0) 28 9445 1011 to speak with one of our experts.
Goodwood Gut Health Summit
Join the exclusive Goodwood Health Summit, presented by Randox Health on Thursday 19th September.
Randox, a leader in the field of diagnostic medicine, is in the forefront of this profound change in health care – one that opens up the possibility of delivering enormous benefits to individuals and society at large.Ā Ā
Justin Webb will lead the conversation with a world-class line up of speakers, including Dr. Chris Van Tulleken, Dr Sioned Jones, Mr James Kinross, and Professor Louise Kenny and discuss evidence around early year feeding and environment.
This year’s summit, sponsored by Randox Health, highlights the urgent need for further research and widespread education on the infant and mother microbiome. With a line-up of world-research and widespread education on the infant and mother microbiome. With a line-up of world-class speakers and a day filled with insightful discussions. The Goodwood Health Summit is a vital event for healthcare professionals, researchers and anyone interested in the health and wellbeing of
future generations.
Key topics to be addressed include:
- The role of breastfeeding in establishing a healthy microbiome
- The impact of ultra-processed foods (UPF) in baby food and their influence on nursing mothers
- Challenges and solutions to enhancing medical and societal understanding of early years nutrition
- The role of lifestyle changes, education, and awareness in promoting better health outcomes
- The influence of commercial and political factors on public health decisions
Goodwood 2023 Health Summit.Ā
What is a gut microbiome?
Picture a bustling city on a weekday morning, the pavements flooded with people rushing to get to work or to appointments. Now imagine this at a microscopic level and you have an idea of what the microbiome looks like inside our bodies, consisting of trillions of micro organisms (also called microbiota or microbes) of thousands of different species.
These include not only bacteria but fungi, parasites, and viruses. In a healthy person, these ‘bugs coexist peacefully, with the largest numbers found in the small and large intestines but also throughout the body. The microbiomes is even labeled a supporting organ because it plays so many key roles in promoting the smooth daily operations of the human body.
A person is first exposed to microorganisms as an infant, during delivery in the birth canal and through the mother’s breast milk. Later on, environmental exposures and diet can change our microbiomes to be either beneficial to health or to place one at greater risk for disease.
Gastrointestinal Diseases Biochip
Why use Biochip?
In the UK, there are one million consultations
In the UK, there are one million consultations per day in primary care. Gastrointestinal (GI) complaints account for up to 10% of these consultations. A further 50% of these consultations are for upper GI symptoms such as dyspepsia (epigastric pain/ indigestion)
Results from a systematic review:Ā Around 80% of patients with dyspepsia had a normal endoscopy. These patients likely had functional dyspepsia (no pathology or obvious cause for symptoms).
Significantly reducing and eliminating the need for:
- Hospital referrals
- Unnecessary Scans
- Endoscopy Procedures
Evidence MultiSTATĀ
The Evidence MultiSTAT is an easy to use, small footprint analyzer facilitating on-site simultaneous detection of multiple biomarkers. Using chemiluminescence as a measurement principle, the Evidence MultiSTAT consistently delivers accurate results. With minimal sample preparation required, this versatile benchtop analyzer can achieve accurate quantitative results in minutes.
The Evidence MultiSTAT cartridge contains the reagents required for the chemiluminescent reaction to take place incorporated into its wells.
The process from sample entry to results can be completed in 2 simple steps, with minimal risk of human error. No other components are required.
To find out more: Gastrointestinal Diseases Clinical Biochip – Randox Laboratories
Randox Health features in Sunday Times article
One writerās first health MoT showed her cholesterol in the red. It forced a dramatic lifestyle rejig, but the hard part was making the changes stick
In February my colleague Matt Rudd sent a pleading email: āHelp! I need volunteers for a blood health panel screening. Hooked on the fact that a million people in the UK have undiagnosed T2 diabetes.ā
My Italian grandmother had diabetes. I had never had a proper health check in my life. It probably wasnāt a bad idea to have an MoT.
By my reckoning, I was in reasonable nick for a 37-year-old mother of a two and a five-year-old: I cooked from scratch, didnāt eat red meat and cycled (occasionally and slowly) to work. I banked on getting the health equivalent of a B+.
But I very much did not get a B+. The results from my Ā£65 āvitalā Randox Health check were graded byĀ a traffic light system. Ten per cent of me was, firmly, in the alarming red zone and 13 per cent was amber. The (main) issue was not pre-diabetes, butĀ high cholesterol. My total was 6.22 mmol (millimoles per litre) when it should have been less than 5.
āIām really freaking out,ā I messaged my partner, Tom. āIām going to get heart disease. Or have a stroke.ā
Closer inspection showed that my LDL, which Google informed me was the bad kind of cholesterol, the kind that clogs up the arteries and kills you, was 3.56. It should have been below 3. My iron levels were also low, again throwing up more red. And I wasnāt fit. My body mass index was in the green but I had the metabolic age of a 40-year-old. āThis is really sub-optimal,ā I added to Tom.
But it was the high cholesterol, which is usually without symptoms, that bothered me. Nearly 50 per cent of the population is estimated to have high cholesterol and it often runs in families, explains Julie Ward, a cardiac nurse at the British Health Foundation. āItās really prevalent in society, but often people, especially younger people, have no idea at all until they get checked. The key is to talk to your relatives, to your parents. Ask them if thereās a family history.ā
I peppered my trim mum with anxious messages. Why didnāt I know about this? āI told you that I had high cholesterol,ā she replied. When? āYou were 14.ā Somewhere between the Smirnoff Ice and Marlboro Lights, that particular health concern apparently hadnāt lodged in my mind.
I told my twin brother about our genetic predisposition, which he seemed relaxed about. I was anything but relaxed. I think it was the recognition that I could no longer āwing itā that struck me. Call it my coming of age. And my worries spiralled from there: I wanted to be around and healthy for my children as they grew up. Which meant that as Sir Keir Starmer said about the NHS, I had two options: reform or die.
The question was: what to do about it? Changing habits, some of which developed in childhood, is extremely challenging. I took a hard-nosed look at my lifestyle. Exercise didnāt really feature, other than the 25-minute cycle to the office and a bit of tennis. None of which, Tom pointed out, made me break into a sweat.
I ate lots of vegetables, fish and pulses, but I also ate cheese straws, crisps and pasta. At restaurants, I was all about fried and/or beige: croquetas, any kind of tempura, burrata, tuna tostadas. The bread basket. Nor did I ever contemplate the long rigmarole of putting our kids to bed without eating a hefty wedge of toasted sourdough, butter and mature cheddar.
So what could I do? The answers were predictable: exercise, cut out saturated fats (found in cakes, biscuits, pastries, processed food), eat more pulses and vegetables, and eat plenty more seeds, nuts, oily fish and avocado, all sources of good cholesterol, the kind that takes the bad away from the arteries.
Letās retest in six months, suggested Matt Rudd. Here was a competition, something I could get on board with.
āIām making radical changes,ā I told Tom as I filled our online Sainsburyās cart with butter beans, chickpeas and beetroot (none of which I much liked). āNo more bread, white pasta, potatoes, white rice. No cheese, no deep-fried food. No moreTonyās Chocolonely. And Iām going to work out two mornings a week.ā
The first major test came two days later when we went on a rare childfree trip to Venice, home of cichetti and Aperol Spritz. At 6pm, drinking white wine beside the lagoon, I was presented with a (free) plate of tiny smoked salmon white bread sandwiches and bruschette piled with salted cod.Oh tentazione!
But I had decided to go cold turkey. Any other approach and I knew my willpower would evaporate before Tom could say āstrokeā. Dinner was torture: obviously I wanted the spaghetti alle vongole but instead I made myself order cuttlefish stew (no carbs!).
Back in London, I carried on. Toast with butter and marmite was replaced with chia and flaxseed-heavy oat bircher. My mid-afternoon snack of pop chips became walnuts and almonds. A salad for the old me was 60 per cent crouton.
Dinner became something like veggie chilli, no rice, or spicy butter beans with spinach and tofu. Biscuits, cakes and puddings were taken off my menu. As was my after-supper chocolate.
Classpass, a monthly subscription that gets you access to various gym classes, also worked for me. Mainly because its policy is to fine you for missing a class. Brutal but effective.
It takes 60 days to form a habit, Tom kept telling me when I wavered: donāt give up. A dogma confirmed by Jenna Hope, a nutritionist who advises her clients on how to break and reform habits. āItās hard, but there are tricks,ā she says. One is to focus on what is making you sit down on the sofa with a tub of ice cream after work. āIf that is what you do for relaxation, you need to replace the ice cream with something else, something healthy. Donāt just say, āIām not having ice cream any moreā, thatās much harder.ā
Each person is different, she says, some need to make changes slowly. Others, like me, need to go nuclear. Either way, the key is consistency.
Competitiveness also drove me. I wanted to beat Matt Rudd. Though when he opened his desk drawer to reveal a supermarket-sized stack of Jammy Dodgers, Mini Cheddars and Haribo, I realised heād given up.
By two months in, I was feeling a hell of a lot of better. I no longer had stomach aches and I was fitter and had lost weight. Iād also developed a taste for crouton-free salad.
Take the Randox test, my editor kept asking me. But I was worried: what if, after all this effort and self-denial, my cholesterol hadnāt changed? Can you even do anything about it when it runs in your family?
Last week, I caved andtook the test. The great news was that I had reduced my metabolic age from 40 to 23. And my cholesterol? Still red but definitely leaning more pink: from a total of 6.22 it had dropped to 5.6. And the bad kind was now at the healthy level, below 3, at 2.79 mmol.
āThatās a really good level,ā said Joanna Lilburn, a scientific consultant at Randox. āAnd I wouldnāt worry about the total level because a lot of that is good cholesterol.ā
Which is what I wanted to hear. Lifestyle changes were working. Albeit slowly. What I didnāt want to hear is that cholesterol levels increase as you age. Which means that now, warned Lilburn, comes the hard part. āItās about keeping it going.ā
Read full article here: I had high cholesterol at 37. The cure was tougher than I imagined (thetimes.com)
Understanding Xanthochromia
Understanding Xanthochromia
When faced with a potential subarachnoid haemorrhage (SAH), the tools we use to diagnose can quite literally be life-saving. Cerebrospinal fluid (CSF) analysis plays a pivotal role, especially when common diagnostic tools like Computed Tomography (CT) scans might not catch early signs.
Traditionally, xanthochromia detection relied on visual assessment – a method that suffers from inconsistency due to subjective interpretation and lacks uniformity across the industry. Today, spectrophotometry has emerged as the preferred method for its precision and reliability in detecting xanthochromia. To ensure the highest accuracy, this technique requires stringent quality control measures. Here, we discuss xanthochromia and SAH, before introducing our dedicated Xanthochromia true third-party control.
What is Xanthochromia?
Xanthochromia, derived from the Greek word, ‘xanthos,’ meaning yellow, refers to the yellow, or sometimes pink, discolouration of CSF, primarily due to bilirubin, a by-product of haemoglobin breakdown. Why does this matter? Because it’s a tell-tale sign of bleeding within the brain, often indicating SAH when CT scans don’t. Understanding this can help us catch and treat critical conditions before they worsen. Xanthochromia may also be an indicator of intracerebral haemorrhage, brain tumours, infection, or severe systemic jaundice1.
Subarachnoid Haemorrhage
SAH is a spontaneous intracranial bleed characterised by significant mortality and morbidity rates. Approximately 12% of patients die before receiving medical attention, 33% within 48 hours, and 50% within 30 days of an SAH. Among the survivors, half suffer from permanent disabilities, with an estimated lifetime cost more than double that of an ischemic stroke2. Patients which have displayed symptoms often complain of severe headache, nausea, vomiting, photophobia and/or phonophobia3.
CT scans, particularly non-contrasted CTs of the brain or CT angiograms (CTAs), are often the first line of diagnostic tools for suspected SAH. However, up to 5% of SAH cases may not show any signs of haemorrhage on these scans within the first 24 hours, with this figure rising to 50% by the end of the first week and remaining around 30% by the second week4.
In contrast, xanthochromia in the CSF can be detected as early as two hours after a bleed and is observed in over 90% of patients within 12 hours of an SAH event. This detection can persist for up to three to four weeks, offering a critical diagnostic window that imaging alone might miss. The conversion from haem to bilirubin in CSF takes roughly 6 to 12 hours, suggesting that xanthochromia is most reliably identified between 6- and 12-hours post-bleed. More than 75% of patients may still present with xanthochromia at 21 days following an SAH1.
Pathophysiology explained
A ruptured cerebral aneurysm will begin to leak blood into the CSF. This blood is gradually degraded by macrophages to yield various by-products including oxyhaemoglobin, which is subsequently converted to bilirubin in a process lasting between 6 and 12 hours1. Crucially, this conversion to bilirubin can only occur in vivo, providing a unique marker for diagnosing subarachnoid haemorrhage when observed in the CSF1.
The Importance of Accurate Detection
In many parts of the world, including the US, visual detection remains a common initial test for xanthochromia in CSF.
- Procedure: Spinning a CSF sample in a centrifuge and comparing the supernatant against a vial of water, held against a white backdrop to detect a yellow or pink tint.
- Indication: A change in colour indicates that blood has been present in the spinal fluid for at least two hours, with all patients showing signs by 12 hours post-bleed1.
However, this method is prone to false positives due to:
- Dietary influences: High intake of carotenoids (like carrots and spinach).
- Medication: Use of Rifampin.
- Medical conditions: Clinical jaundice or high protein levels in CSF, which can be seen in conditions like carcinomatosis and meningitis1.
Spectrophotometry
Spectrophotometry offers a more precise alternative by measuring light absorption in materials at specific wavelengths:
- It can detect the presence of bilirubin, which absorbs light at 440 to 460 nm, a definitive indicator of xanthochromia.
- Advantages over visual detection: This method eliminates the interference from other pigments or proteins and can distinguish bilirubin from oxyhaemoglobin, crucial for accurate diagnosis.
Quality control is crucial in spectrophotometry to ensure the accuracy and reliability of xanthochromia tests:
- Regular Maintenance: Routine checks and maintenance of the spectrophotometer are fundamental to its operation. This helps in maintaining the instrument’s precision in measuring light absorption at specific wavelengths crucial for detecting bilirubin in CSF.
- Calibration: Calibrating the spectrophotometer with known standards is essential. This process adjusts the instrument to measure the absorption accurately, particularly vital given bilirubin’s narrow detection window between 440 and 460 nm.
Implementing these stringent QC measures enhances the diagnostic precision of spectrophotometry, boosting confidence in the results. Such practices ensure that patients are diagnosed accurately and receive timely, appropriate treatment, solidifying the value of advanced diagnostic techniques in medical settings.
Introducing Randox Xanthochromia Controls
Diagnosing SAH swiftly and precisely is critical due to its significant immediate and long-term impacts. To aid precise detection, our Liquid Frozen Xanthochromia Positive & Negative Controls are essential tools for laboratories conducting CSF analysis. Here’s what makes them stand out:
- Dedicated Xanthochromia true third-party control with only 2 analytes for limited cross-reactivity – Bilirubin & Oxyhaemoglobin
- 2-day open vial stability at 2° to 8°C and a 11-week shelf life from date of manufacture when stored at -18ºC to -24ºC.
- Liquid frozen control provides suitable matrix in an easy-to-use format.
- Consistent, clinically significant values.
- Suitable for use with UV spectrophotometers, these controls help monitor bilirubin and oxyhaemoglobin levels effectively.
The Randox Xanthochromia Controls are ideally suited for laboratories, both public and private, as well as researchers who perform CSF analysis. Their use is crucial in ensuring the precision of SAH testing, which contributes to more accurate diagnostics and ultimately leads to better patient outcomes.
Considering the crucial role of accurate xanthochromia detection in diagnosing SAH, isn’t it time to review your lab’s capabilities? Explore how Randox Xanthochromia Controls can enhance your diagnostic processes. For more details on how to get these tools in your lab, contact us at marketing@randox.com.
In the fight against conditions like SAH, every second and every test counts. Equip your lab with Randox Xanthochromia Controls to ensure that your diagnostics are as precise and reliable as possible, helping save lives and improve healthcare outcomes.
References
-
- Dugas C, Jamal Z, Bollu PC. Xanthochromia. StatPearls Publishing; 2024. Accessed August 5, 2024. https://www.ncbi.nlm.nih.gov/books/NBK526048/
- Sehba FA, Hou J, Pluta RM, Zhang JH. The importance of early brain injury after subarachnoid hemorrhage. Prog Neurobiol. 2012;97(1):14-37. doi:10.1016/j.pneurobio.2012.02.003
- NHS. Subarachnoid haemorrhage. https://www.nhs.uk/conditions/subarachnoid-haemorrhage/.
- Chakraborty T, Daneshmand A, Lanzino G, Hocker S. CT-Negative Subarachnoid Hemorrhage in the First Six Hours. Journal of Stroke and Cerebrovascular Diseases. 2020;29(12):105300. doi:10.1016/j.jstrokecerebrovasdis.2020.105300
Routine healthcare could save billions and boost survival rates for cancer and serious diseases.
Reports show that “improvement in life expectancy have ground to a halt” and more than one in five deaths are considered “avoidable”. It warns that since the 1960 the UK has “declined from being ranked first for life expectancy among G7 countries to being ranked second last”.Ā
Dr. FitzGerald said: “This is a shameful drop of quality care, and it should be a national disgrace that our healthcare provider has failed us so badly.”
Pushing for the UK to follow the example of Japan, where the average person can expect to live more than 84 years, he said: “Japan is leading the way in healthcare testing. It has the highest life expectancy of all G7 nations, and it routinely tests for far more than we do in the UK.
“Major benefits for them have included a massive 25 per cent fall in diabetes rates among those at risk of developing the disease.”
The Office for National Statistics sounded the alarm bell about declining life expectancy in the UK earlier this year. Life expectancy at birth for men in the 2020-22 period fell by 38 weeks to 78.6 compared with 2017-2019;Ā for women, it went down by 23 weeks to 82.6 years.
There is strong concern that in Britain people are much more likely to enjoy long lives if they are better off. In 2021, there was alarm when it was reported that a man living in Kensington and Chelsea, one of the country’s richest areas, could be expected to live 27 years longer than a counterpart in Blackpool.
Dr. FitzGerald is pushing for a far more ambitious programme of testing than the health MOTs offered to people aged 40-plus on the NHS.
Claiming that the “NHS is creaking at the seams”, he said: “By investing in preventative measures, the NHS will be far more effective and therefore far better value for money for the taxpayer.”
The biochemist, who in 1982 founded his company in a converted chicken house in Crumlin in Northern Ireland, argues Britain “must do better”. He said, “Improving the health and prosperity of the nation is an important goal – and this initiative can more than pay for itself. More importantly, it will be greater than a simple money saving exercise.
It can and will save lives. It is time for government to step up and deliver for the British people. A Department for Health and Social Care spokeswoman said: “We will transform the NHS from a late diagnosis, late treatment health service, to one that catches illness earlier and prevents it in the first place. We will start by doubling the number of diagnostic scanners to help speed up diagnosis and treatment.”
Dr. FitzGerald is pushing for a far more ambitious programme of testing than the health MOTs offered to people aged 40–plus on the NHS. Claiming that the ‘NHS’ is creaking at the seems, he said: “By investing in preventative measures, the NHS will be far more effective and therefore far better value for money for the taxpayer.
“More importantly, it will be greater than simple money saving exercise.Ā It can and will save lives. It is time for the government to step up and deliver for the British people. A Department for Health and Social Care spokeswoman said: “We will transform the NHS from a late diagnosis, late treatment health service, to one that catches illness earlier and prevents it in the first place. We will start by doubling the number of diagnostic scanners to help speed up diagnosis and treatment.”
Health Secretary Wes Streeting has ordered a ‘full and independent investigation into the state of the NHS to uncover the biggest challenges facing the health service.
Words by David Williamson, The Sunday Express
Randox Health ā Optimising Performance as Official Diagnostic Health partner of Team GB for Paris 2024
Randox Healthās unique diagnostic technologies have been supporting Team GB throughout their journey to the Paris 2024 Olympic Games ā from preparation to their hard-earned success of over 40 Olympic medals and will continue to help optimise the teamās performance during the remainder of the competition.Ā
Randoxās Vivalytic diagnostics machine has been in action during Paris 2024. These fully automated, all-in-one molecular diagnostic machines are powered by Randoxās unique Biochip Technology and are capable of checking for a wide range of respiratory infections, enabling multiple test results from just one sample.
āAs a Sport and Exercise Medicine Consultant working with elite athletes, itās important we know the pathogen driving the disease process to be able to target management appropriately. With Randox supplying this useful technology in our performance environments, we can optimally manage both the athletes and wider team safely and efficiently.ā
āOur aim, along with the teams of experts assisting our athletes is simple ā to ensure that Team GB is in peak physical and mental condition as they get to the starting line.ā Dr. Lisa Hyland, who is working as a Team GB HQ Doctor
Find out how Randox Technologies help Team GB reach Olympic success with our Vivalytic Point of Care testing
Team GBās Chief Medical Officer, Niall Elliott, said that Randox was helping in three critical areas of health testing for athletes ā iron metabolism, vitamin D levels ā critical to the immune system and muscle power ā and glucose or energy levels. āIt is a fascinating journey, the testing we can do.ā
Over the last year, Randox have been working closely with Team GB brand ambassadors, to ensure they are perfectly placed to perform their utmost at the Olympic Games. Each of them have undertaken a Randox Health Everyman and Everywoman diagnostic health test package at one of the Randox Health clinics, to measure their conditions as they get to that starting line in Paris.
As one star, Duncan Scott, Team GBās most decorated Olympic swimmer, put it: āIf it makes one per cent difference itās 100% worth it.ā
āEverything you do as a swimmer is being channelled through the window of your technique but thereās external factors such as nutrition, recovery, sleep that contribute those one percents towards how youāre going to be inside the pool when it matters the most. With that in mind, I think the Randox Health Everyman check was spot on and Iām glad that Iāve done it.ā
Team GB sprinter and double Olympic medallist Daryll Neita the Everywoman test, calling it, āthe most in-depth testing Iāve ever had.ā
āItās amazing that the Everywoman test discovers things that could help my performance whether itās how I recover to deficiencies but also our sport is about marginal gains, centimetres, millimetres, the finest of margins and through tests like this, it lets you stay on-top of your health helping you achieve optimal performance or even a mental boost that youāre healthy.ā
Adds Dr. Peter FitzGerald, Founder and Managing Director of Randox Health, āAnd these technologies are not just for athletes ā our diagnostic packages and analysers are designed to make a difference to everyoneās life ā to help us make the most of all the opportunities life has to offer.ā
Blood test for over-40s could save the economy Ā£12bn a year if offered on NHS – OCO report
The NHS currently offers health MOTs to patients aged 40 to 75. However, the five-yearly check is normally limited to blood pressure and cholesterol, along with height, weight and waist measurements.
Diagnostic firms sell private blood tests which can check for 200 types of disease, including most common cancers.
A report by OCO Global, an independent consultancy firm, says that if the NHS provided these more comprehensive health checks, problems would be detected far earlier, ultimately saving lives and money.
The research, which has been sent to Wes Streeting, the Health Secretary says that although each check would cost around Ā£230 – a bill for the NHS of around Ā£650 million a year – they would reap major rewards.
Modelling suggests that, after 16 years, the annual boost to the economy would amount to Ā£11.7 billion – Ā£1.83 billion in treatment costs, around Ā£5.8 billion wider savings from health improvements and an indirect benefit of Ā£4 billion – based on the assumption that around half of people take up the tests.
The report was commissioned by Randox, the UK’s biggest diagnostics firm, which carried out millions of PCR tests during the Covid-19 pandemic.
It claims that the blood testās 200 data points would enable far earlier diagnosis, similar to an approach in countries such as Japan and South Korea, where the checks are mandatory and linked to health insurance.
In Japan, which has the highest life expectancy of all G7 nations, such checks have seen a 25 per cent fall in diabetes rates, among those suffering from pre-diabetes rates, among those suffering from pre-diabetes.
The report highlights the intense pressures on the NHS, with waiting list of more than seven million, and 185 million working days lost to sickness every year.
“For too long the UK has been behind the curve on health testing, with less testing carried out than any other developed country. This means that serious diseases are detected too late, with the consequence of more cost for the NHS, more suffering for the patient, and often premature death.ā David Davis, former chairman of the Commons Public Accounts Committee
āImproving the health and prosperity of the nation is a lofty goal – and the report shows this initiative can more than pay for itself.āDr Peter FitzGerald, Randoxās managing director
Words by Laura Donnelly, The Telegraph
Read full article here: https://www.telegraph.co.uk/news/2024/08/04/nhs-cancer-blood-test-save-12bn-research/
Alzheimer’s Disease, ApoE & Risk Detection
Alzheimer’s Disease, ApoE4 & Risk Detection
Alzheimer’s disease touches all of us, whether directly through an affected loved one or through its frequent presence in the news. Alzheimer’s disease is a progressive neurodegenerative disorder characterised by cognitive decline, memory loss, and functional impairments. It is the most common cause of dementia, affecting millions of individuals worldwide 1 and posing significant challenges to healthcare systems. As the global population ages, the prevalence of Alzheimer’s disease is expected to rise, highlighting the urgent need for effective diagnostic and therapeutic strategies.
The current methods used to diagnose Alzheimer’s disease consist of clinical assessment and supporting neuroimaging techniques which can be expensive and, in some cases, fail to provide a definitive diagnosis at the early stages required to facilitate timely intervention and slow disease progression.
With novel therapeutics which aim to slow the progression of Alzheimer’s Disease achieving approval in the United States and being considered for approval in other countries, diagnostics which can identify those at risk of developing this disease are more important than ever. Biomarkers have emerged as vital tools in the early detection and risk assessment of Alzheimer’s disease. Among these, the apolipoprotein E gene (ApoE) has garnered significant attention. The apolipoprotein E protein (ApoE) exists in three common isoforms: ApoE2, ApoE3, and ApoE4. These isoforms combine to form six common genotypes in the general population. Notably, the presence of the ApoE4 allele is associated with a significantly increased risk of developing Alzheimer’s disease.
The Randox ApoE4 Array marks a significant advancement in Alzheimer’s disease biomarkers. This quick and sensitive blood test allows direct ApoE4 genotyping, eliminating the need for traditional molecular techniques. With its fast and accurate results, healthcare providers can efficiently assess an individual’s genetic risk for Alzheimer’s disease.
In this article, we present a summary of our latest whitepaper: Alzheimer’s Disease, ApoE4 & Risk Detection in which we explore the critical role of ApoE genotyping in Alzheimer’s Disease, the innovative technology behind the Randox ApoE4 Array, and its implications for clinical practice. You can download this whitepaper through the link below.
Apolipoprotein E and Alzheimer’s Risk
The ApoE gene transcribes a 229 amino acid protein which primarily functions to mediate lipid transport in the brain and periphery. ApoE is also involved in immune modulation, synapse regeneration, and the clearance/degradation of amyloid-β, a peptide crucial to the development of Alzheimer’s disease2.
There are 3 common isoforms of the human ApoE, differentiated through single nucleotide polymorphisms (SNPs) at amino acid positions 112 and 1582:
These three isoforms combine to produce six common genotypes: E2/E2, E2/E3, E2/E4, E3/E3, E3/E4, and E4/E4. Each genotype is associated with a different level of risk for developing Alzheimer’s disease, with the ApoE4 and ApoE2 isoforms presenting the highest3 and lowest risk 4 respectively.
The structural differences among ApoE isoforms affect their ability to bind lipids, receptors, and amyloid-β, influencing cognitive decline. ApoE2 and ApoE3 bind effectively to HDL (High density lipoprotein), while ApoE4 binds to VLDL (Very low-density lipoprotein), resulting in poor lipidation and toxic aggregates1,2. Cholesterol is crucial for brain function, supporting membrane integrity, signal transduction, and amyloid-β regulation. The interaction of ApoE with amyloid-β regulates amyloid plaque formation, influencing Alzheimer’s disease onset. Cholesterol must be converted to 24S-hydroxycholesterol to cross the blood-brain barrier. Poor cholesterol and phospholipid transport by ApoE4 increases the risk of late-onset Alzheimer’s disease in E4 carriers2.
Randox ApoE Array
The Randox ApoE4 Array is a rapid and highly sensitive blood test that facilitates direct ApoE4 genotyping without the need for traditional molecular techniques. It measures both total ApoE and ApoE4 protein levels directly from a plasma sample, using the ApoE4/total ApoE ratio to classify the ApoE4 status as negative or positive. Additionally, the array can distinguish between heterozygous and homozygous individuals among ApoE4 positive samples, aiding in the assessment of Alzheimer’s disease risk.
Using Randox proprietary chemiluminescent biochip-sandwich immunoassays, the array provides accurate results within three hours from a minimally invasive plasma sample. This method has shown 100% concordance with genotypes achieved through restriction fragment length polymorphism (RFLP) in two separate centres5. Compared to other methods like isoelectric focusing, mass spectrometry, bead-based immunoassay, Sandwich ELISA, and PCR, the Randox ApoE Array offers advantages in speed, simplicity, and automation.
Clinical Implications
The Randox ApoE Array offers significant benefits for managing Alzheimer’s disease through early detection and personalised treatment plans. This minimally invasive blood test identifies individuals at higher genetic risk for Alzheimer’s Disease enabling:
- Timely Interventions: Early identification allows for preventive measures and lifestyle modifications, such as cognitive training and increased physical activity, to delay symptom onset.
- Regular Monitoring: High-risk individuals can be monitored for cognitive changes, enabling early intervention for mild cognitive impairment.
Personalised Treatment Plans
Accurate ApoE genotyping supports personalised treatment:
- Targeted Therapies: ApoE phenotype informs the selection of therapies, especially for ApoE4 carriers.
- Risk Stratification: Patients can be stratified by genetic risk for targeted preventive measures.
- Optimised Medication: Genotype information guides medication choices, enhancing efficacy.
- Family Counselling: Genotyping aids family counselling, advising on preventive measures and monitoring.
Conclusions
The Randox ApoE Array represents a groundbreaking advancement in the early detection and management of Alzheimer’s disease. By providing a rapid, highly sensitive, and minimally invasive method for ApoE genotyping, it empowers healthcare providers to implement timely interventions and personalised treatment plans. This innovative approach not only enhances the accuracy of Alzheimer’s risk assessment but also supports the development of targeted therapies and optimised medication regimens, ultimately improving patient outcomes.
Early detection of Alzheimer’s disease allows for proactive measures that can delay the onset of symptoms, while personalised treatment strategies tailored to an individual’s genetic profile offer a more effective management approach. Furthermore, the array’s capability to provide real-time insights into a patient’s disease stage makes it an invaluable tool in the fight against Alzheimer’s disease.
For a deeper understanding of the critical role of ApoE genotyping in Alzheimer’s disease and the innovative technology behind the Randox ApoE Array, we invite you to download our comprehensive whitepaper be clicking on the image below. You can also visit our website to access this and other valuable resources and to learn more about the Randox ApoE4 Array.
References
- Raulin AC, Doss S V., Trottier ZA, Ikezu TC, Bu G, Liu CC. ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies. Mol Neurodegener. 2022;17(1):72. doi:10.1186/s13024-022-00574-4
- Husain MA, Laurent B, Plourde M. APOE and Alzheimer’s Disease: From Lipid Transport to Physiopathology and Therapeutics. Front Neurosci. 2021;15. doi:10.3389/fnins.2021.630502
- Qian J, Wolters FJ, Beiser A, et al. APOE-related risk of mild cognitive impairment and dementia for prevention trials: An analysis of four cohorts. PLoS Med. 2017;14(3):e1002254. doi:10.1371/journal.pmed.1002254
- Reiman EM, Arboleda-Velasquez JF, Quiroz YT, et al. Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study. Nat Commun. 2020;11(1):667. doi:10.1038/s41467-019-14279-8
- Badrnya S, Doherty T, Richardson C, et al. Development of a new biochip array for APOE4 classification from plasma samples using immunoassay-based methods. Clinical Chemistry and Laboratory Medicine (CCLM). 2018;56(5):796-802. doi:10.1515/cclm-2017-0618
The medical techniques keeping Team GB healthy during the Olympic Games
There was a time when you could count the number of British gold medallists on the fingers of one hand. Back in the 1960s and 1970s, winning an Olympics event made you a household name overnight.
Anne Packer, Lynn Davies, Mary Peters, David Hemery, Anita Lonsbrough, ā to name a few of the few ā were feted across the land to pulling off the seemingly impossible ā beating the world, usually in track and field or the swimming pool.
But all that has changed.
London 2012 (29 gold medals); Rio de Janeiro 2016 (27 gold); Tokyo 2020 but actually in 2021 (22 gold).
Time was when most Olympics hopefuls were fanatical amateurs, prepared to turn out on some bleak and chilly track, strip down to their shorts and practise their sport in front of an equally dedicated but minority audience.
Not any more. The British medals haul, however you measure it, is also top of the tree on an international basis. A country of fewer than 70 million people typically comes in the top three or four on the planet behind only the likes of such giants such as the USA and China. We even beat the Australians ā on a regular basis.
This has not happened by accident.
Obviously, a huge amount of credit must go to the athletes themselves and their coaches. Their talent and dedication will be fully on display in Paris this week when the Games return to France for the first time in exactly 100 years.
But there is much more to it than that.Ā Team GBĀ has revolutionised British Olympics in recent years. The team numbers more than 300 and for only the second time in our history, there will be more women (172) than male (155) competitors.
Professional coaches, physios, nutritionists, and mind game experts will abound.
The Greatest Show on Earth will dominate our TV screens, social media, press and national conversation for a fortnight (and more).
These are some of the reasons why Randox, Europeās biggest diagnostic company, is sponsoring Team GB. We love supporting the athletes behind mega sporting events (The Grand National, for instance) and it does not come any more mega than Paris 2024.
We were there the last time ā Tokyo 2020 ā but in challenging circumstances. Tokyo 2020 actually took place in 2021, postponed for a year because of theĀ CovidĀ pandemic.The glittering contests were performed in front of empty stadiums and sports halls after the Olympic authorities, understandably anxious to avert a super-spreader car crash, prohibited spectators.
Founded in 1982, Randox conducted more than 27 millionĀ CovidĀ tests in the UK and offered support to Team GB three years ago for a very specific and vital purpose ā to help stop the spread ofĀ CovidĀ among the athletes and their support teams. It worked. Despite the fears of the Olympic authorities, the plethora of measures taken to safeguard contestants, meant that only one athlete fell sick and was unable to compete.
Not so this time. 15 million people, two million from abroad, are expected to swamp the French capital over late July and early August.
Our Vivalytic diagnostic machine, used in Tokyo to test all our athletes forĀ Covid, will be in action again. But this time, we will be casting the net far wider, checking for a range of respiratory infections that can lay contestants low.
Our aim, along with the teams of experts assisting our athletes is simple ā to ensure that Team GB is in peak physical and mental condition as they get to the starting line.
We have also been working closely with our brand ambassadors to ensure that they are perfectly placed to perform to their utmost in Paris. All of them have undertaken our Everyman and Everywoman diagnostic health testing packages at one of our health clinics, to measure their condition as they prepare for Paris.
As one star, Duncan Scott, our most decorated Olympic swimmer, put it: āIf it makes one per cent difference, itās 100 per cent worth it.
āIt excited me that it was essentially a head-to-toe MOT and thereās areas Iāve never really had much data, on but also last year I had an IgE (antibody) deficiency impacting my immune system which made training so inconsistent as some days I felt sluggish.
āThis year has been much more consistent after picking up on it which makes me wish I had something like this, as if I did this last year or 24 months ago, itād have been ideal going in unknown and then picking up on it as a risk rather than me getting frustrated and being ill.ā
Top sprinter Daryll Neita, a multiple medal winner, took the Everywoman test, āthe most in-depth testing Iāve ever had.ā
Her verdict points to the confidence boost of knowing you are in peak condition physically: āAlthough Iāve not had any recent health concerns, itās amazing that the Everywoman test discovers things that could help my performance.
āWhether itās how I recover or deficiencies, but also our sport is about marginal gains, centimetres, millimetres, the finest of margins and through tests like this, it lets you stay on-top of your health, helping you achieve optimal performance or even a mental boost that youāre healthy.ā
Team GBās Chief Medical Officer Niall Elliott, said that Randox was helping in three critical areas of health testing for athletes ā iron metabolism, vitamin D levels – critical to the immune system and muscle power – and glucose or energy levels. āIt is a fascinating journey, the testing we can do.ā
This must be the best prepared ā and the most safeguarded ā Team GB ever to leave our shores.
As devotees of the wonderful film, Chariots of Fire, will know, they have much to live up to. Back in the 1924 Paris Olympics, Harold Abrahams in the 100 metres and Eric Liddell in the 400 metres both emerged triumphant. On top of their legendary feats, Britain secured seven more gold medals.
We can only hope and pray that our champions, bolstered by the latest in sports science, can achieve even greater heights.
Words by Dr. Peter FitzGerald, Sunday Express https://www.express.co.uk/news/politics/1925873/medical-techniques-keeping-team-gb
Active vs Total Vitamin B12
Total vs Active B12
Vitamin B12, or cobalamin, is a vital water-soluble vitamin that plays an essential role in myelination initiation and development, cellular energy and fatty acid metabolism. It is a cofactor for enzymes methionine synthase and L-methyl-malonyl-coenzyme A mutase and, in addition to folate, is essential for DNA and protein synthesis. In the UK, up to 6% of adults under 60 have been diagnosed with Vitamin B12 deficiency and figures are much higher in elderly populations1. Additionally, these data do not consider the high rates of missed diagnosis associated with B12 deficiency, which some reports claim to be as high as 26%2. New guidance from the National Institute of Health and Care Excellence (NICE) advise that Active vitamin B12 testing is recommended for some groups of patients. In this article, we’ll look at this essential vitamin, B12 deficiency and the associated complications, compare the biomarkers used to diagnose B12 deficiency, and finally, present the new Acusera Active B12 Control.
Aetiology
Vitamin B12 deficiency can arise due to dietary insufficiency, malabsorption resulting from damage to the small intestine, often caused by conditions like Coeliac disease or Crohn’s disease, or via pernicious anaemia – an autoimmune condition which results in an inability to absorb vitamin B12.
It is a common problem in the elderly population – bodily stores of vitamin B12 can take up to 20 years to become depleted, meaning complications have often already begun before diagnosis occurs. The most common source of vitamin B12 comes from dietary intake of animal products therefore vegetarian dietary requirements are considered a considerable risk factor for vitamin B12 deficiency.
Pathophysiology and Complications
Vitamin B12 deficiency significantly impacts health, affecting various bodily functions, potentially leading to a range of complications. Megaloblastic anaemia is a common complication associated with vitamin B12 deficiency and is characterised by the presence of large red blood cell precursors (megaloblasts) in the bone marrow3. The lack of vitamin B12 results in impaired DNA synthesis and an inhibition of nuclear division. However, cytoplasmic maturation is less effected. This results in asynchronous maturation of the nucleus and cytoplasm in erythrocytes and causes the synthesis of abnormally large megaloblasts. This causes the cessation of DNA synthesis and DNA replication errors, culminating in apoptotic cell death. Common symptoms of megaloblastic anaemia include weakness, shortness of breath, palpitations, tachycardia, Hunter glossitis or splenomegaly3.
Pernicious anaemia is a condition commonly associated by vitamin B12 deficiency. Pernicious anaemia is an autoimmune disorder which affects the gastric mucosa resulting in impaired absorption of vitamin B12. Common symptoms of pernicious anaemia include glossitis, hair loss, dry skin, memory loss, poor concentration, poor sleep, confusion and dizziness, shortness of breath, Diarrhoea, indigestion, loss of appetite, mood swings and suicidal thoughts.
Neurological issues may also arise, including numbness, mobility loss, and memory issues, and in some cases, depression4. Additionally, B12 deficiency is linked to increased risks of cardiovascular events5, infertility6, and autoimmune diseases like multiple sclerosis7 and lupus8. In children, vitamin B12 deficiency can manifest as failure of brain and overall growth and development, developmental regression, hypotonia, lethargy, hyperirritability, or coma9.
Active B12 as a marker of Deficiency
There are several markers of vitamin B12 deficiency. The most used in clinical practice are total vitamin B12, homocysteine, methylmalonic acid (MMA), and Holotranscobalamin (HoloTC) – also known as Active B12. HoloTC accounts for between 10-30% of total B12 and is the metabolically active form of vitamin B12.
When compared with total B12 quantification, HoloTC measurement has been shown to be a more sensitive and specific biomarker of B12 deficiency, particularly at borderline clinical levels10, in various cohorts11,12 including those on vegan diets13 – a known risk factor for B12 deficiency. Furthermore, HoloTC was shown to provide the higher diagnostic accuracy in clinical and subclinical B12 deficiency versus Total B12, MMA and homocysteine with significantly higher accuracy in women over 5011 – a population at high risk of B12 deficiency.
In response to the mounting evidence of the superior utility of HoloTC quantification, the National Institute for Health and Care Excellence (NICE) have produced new guidelines recommending either total B12 or HoloTC for the initial testing of suspected vitamin B12 deficiency. These guidelines specify the use of active B12 during pregnancy and suggest that active B12 might provide a more specific assessment in certain clinical contexts.
Acusera Active B12 Control
For the reasons stated above, Randox are proud to present the Acusera Active Vitamin B12 Control. This control is designed for use with in vitro diagnostic assays for the quantitative determination of HoloTC in human serum and plasma and is suitable for use on a variety of analysers. This true third-party control is provided in a liquid ready-to-use format reducing preparation time and has an impressive 30-day open vial stability, helping to minimise waste. Like all Acusera controls, the Active B12 Control is supplied at consistent, clinically relevant levels to ensure the test system is challenged at the critical decision limits used to aid diagnosis. Furthermore, this control is provided with assayed target values for a range of analysers which are available through our new SmartDocs portal.
Summary of Benefits:
- Dedicated, HoloTC control.
- 30-day Open Stability.
- 2-year shelf life.
- Liquid Ready-to-use.
- Human Serum Based.
- Consistent, clinically significant values.
- True third-party controls.
- Assayed target values.
Ensure the accuracy of your vitamin B12 testing with Randox’s Acusera Active Vitamin B12 Control. Join the other laboratories around the world who trust Acusera to help deliver reliable, clinically relevant test results. Contact us today at marketing@randox.com to learn more and order your supply of the Acusera Active B12 Control.
References
- Hunt A, Harrington D, Robinson S. Vitamin B12 deficiency. BMJ. 2014;349(sep04 1):g5226-g5226. doi:10.1136/bmj.g5226
- Oh RC, Brown DL. Vitamin B 12 Deficiency Clinical Manifestations of Vitamin B 12 Deficiency. Vol 67.; 2003. www.aafp.org/afp
- Hariz A, Bhattacharya PT. Megaloblastic Anemia. StatPerals Publishing; 2024.
- Patel S V., Makwana AB, Gandhi AU, Tarani G, Patel J, Bhavsar V. Factors associated with vitamin B12 deficiency in adults attending tertiary care Hospital in Vadodara: a case control study. Egypt J Intern Med. 2022;34(1):11. doi:10.1186/s43162-022-00104-0
- Pawlak R, Parrott SJ, Raj S, Cullum-Dugan D, Lucus D. How prevalent is vitamin B12 deficiency among vegetarians? Nutr Rev. 2013;71(2):110-117. doi:10.1111/nure.12001
- Green R, Graff JP. Megaloblastic Anemia. In: Atlas of Diagnostic Hematology. Elsevier; 2021:47-51. doi:10.1016/B978-0-323-56738-1.00004-X
- Najafi MR, Shaygannajad V, Mirpourian M, Gholamrezaei A. Vitamin B(12) Deficiency and Multiple Sclerosis; Is there Any Association? Int J Prev Med. 2012;3(4):286-289.
- Segal R, Baumoehl Y, Elkayam O, et al. Anemia, serum vitamin B12, and folic acid in patients with rheumatoid arthritis, psoriatic arthritis, and systemic lupus erythematosus. Rheumatol Int. 2004;24(1):14-19. doi:10.1007/s00296-003-0323-2
- Stabler SP. Vitamin B12 Deficiency. New England Journal of Medicine. 2013;368(2):149-160. doi:10.1056/NEJMcp1113996
- Bondu JD, Nellickal AJ, Jeyaseelan L, Geethanjali FS. Assessing Diagnostic Accuracy of Serum Holotranscobalamin (Active-B12) in Comparison with Other Markers of Vitamin B12 Deficiency. Indian Journal of Clinical Biochemistry. 2020;35(3):367-372. doi:10.1007/s12291-019-00835-y
- Jarquin Campos A, Risch L, Nydegger U, et al. Diagnostic Accuracy of Holotranscobalamin, Vitamin B12, Methylmalonic Acid, and Homocysteine in Detecting B12 Deficiency in a Large, Mixed Patient Population. Dis Markers. 2020;2020:1-11. doi:10.1155/2020/7468506
- Verma A, Aggarwal S, Garg S, Kaushik S, Chowdhury D. Comparison of Serum Holotranscobalamin with Serum Vitamin B12 in Population Prone to Megaloblastic Anemia and their Correlation with Nerve Conduction Study. Indian Journal of Clinical Biochemistry. 2023;38(1):42-50. doi:10.1007/s12291-022-01027-x
- Lederer AK, Hannibal L, Hettich M, et al. Vitamin B12 Status Upon Short-Term Intervention with a Vegan Diet—A Randomized Controlled Trial in Healthy Participants. Nutrients. 2019;11(11):2815. doi:10.3390/nu11112815